Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lysogene

www.lysogene.com

Latest From Lysogene

Juggling Gene Therapies: Sarepta's Focus Grows, With Many Balls In The Air

CEO Doug Ingram talked with Scrip about Sarepta's plans to quickly build out a gene therapy pipeline, potentially launch another exon-skipping drug this year and to develop micro-dystrophin for Duchenne muscular dystrophy.

Regenerative Medicine Rare Diseases

Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy

Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.

Research & Development Neurology

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals... 

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Lysogene SAS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Lysogene
  • Senior Management
  • Karen Aiach, Pres. & CEO
    Mark Plavsic, PhD, CTO
    Ralph Laufer, CSO
    Sophie Olivier , MD, CMO
    Sean O’Bryan, VP, Reg. Affairs & Quality Assurance
    Philippe Mendels-Flandre, COO
  • Contact Info
  • Lysogene
    Phone: 1 41 43 03 90
    18-20 rue Jacques Dulud
    Neuilly-sur-Seine, 92 200
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register